Particle.news
Download on the App Store

Indian Visitor Says US Charged Far More for 'Made in India' Drugs

His viral account highlights that high list prices, partial insurance discounts and telemedicine delays can still leave patients with large out‑of‑pocket US medical bills.

Overview

  • In a viral X post reported widely on Monday, Adhir Sinha said medicines he buys for about ₹2,500 in India were listed at the US equivalent of roughly ₹42,000 and that a 50% insurance discount left him paying about ₹21,000.
  • Sinha said the pills bore an Indian maker’s label (Cipla) and that he later received a separate $283 doctor’s bill after a roughly 10‑minute video consultation arranged about a week after he requested care.
  • He described access delays: a general‑physician televisit scheduled a week out, a pharmacy warning that prescriptions would take four to five days to arrive, and a total wait he summarized as 12 days to replace medicines.
  • News outlets in India have echoed Sinha’s post but the reports cite his account rather than independent confirmation from the US provider, the insurer, or Cipla representatives.
  • The story has driven a public conversation about trade‑offs between price, access and quality of life for retirees, and it underscores how US drug pricing and insurance design can leave visitors exposed to sizeable bills.